Clinical study on Psychopharmacological therapeutic efficacy of Vidarikand in Management of Chittodwega (GAD)

Clinical study on Psychopharmacological therapeutic efficacy of Vidarikand (Pueraria tuberosa Roxb. ex Willd) in the Management of Chittodwega (Generalized Anxiety Disorder) - An Open Randomized Controlled Clinical trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/01/079152

Enrollment

Registered

2025-01-21

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F411- Generalized anxiety disorder

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients having cardinal symptoms of GAD for more than 6 months

Exclusion criteria

Exclusion criteria: Patients below 18 and above 39 years Patients with other ADs like OCD, BPD, phobias etc. Pregnant and lactating women Immunocompromised patients Patients with Substance abuse disorders

Design outcomes

Primary

Measure	Time frame
Reduction in Anxiety symptoms, as measured by HAM-A, DASS 21, AAA Scale over the course of interventionTimepoint: 60 days	—

Secondary

Measure	Time frame
Reduction in Anxiety and its symptomsTimepoint: 60 days	—

Countries

India

Contacts

Public ContactDr Charushila Giri

D.Y. Patil School of Ayurveda

charushila.giri@dypatil.edu9892356496

Outcome results